Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New program aims to help seniors kick the sleeping pill habit

NCT ID NCT06584513

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests a patient-centred program to help older adults (65+) reduce or stop using sleeping pills like benzodiazepines. The program includes a tapering plan, educational materials, and cognitive behavioural therapy tools. Researchers will track whether participants can cut back safely and improve their sleep quality.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioural intervention (tapering plan, educational materials, cognitive behavioural therapy elements)
What this could lead to
If successful, this could provide a safe, effective way for older adults to stop relying on sleeping pills, reducing fall risks and other side effects.
What could go wrong
This is a relatively small implementation study, not a large-scale trial. The intervention may not work for everyone, and some people may need to continue medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 470 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥65 years old * BSH (ATC codes N05BA, N05CF, N05CD, and N03AE01) use on average ≥3 times a week during the last 3 months prior to providing informed consent, as self-reported by the patient or by the informal carer * Taking BSH for sleep problems, as self-reported by the patient or by the informal carer Exclusion Criteria: * Indication for BSH appropriate or withdrawal dangerous, based on available documents (diagnosis list) or General Practitioner (GP) information: * Current use of BSH for alcohol withdrawal * BSH use in the context of addiction * Rapid Eye Movement (REM) sleep Behaviour Disorders * Active diagnosis of severe non-REM-related parasomnias with risk of self-damage or giving harm to others or with high frequency or social embarrassment * Epilepsy (all forms, because of risk of seizures by sleep deprivation) * Current active diagnosis of severe general or specific anxiety disorder (including obsessive compulsive disorder, social phobia, post-traumatic stress disorder, panic disorder with or without agoraphobia) * Current active diagnosis of psychotic disorder with or without antipsychotic medication * Current active diagnosis of severe depression with or without major anxiety symptoms * Current active diagnosis of bipolar disorder with or without major anxiety symptoms * Acute suicidal ideation * Current formal active tapering process of BSHs supported by a physician * Planned admission to palliative care within 24 hours of inclusion or estimated life-expectancy of less than 12 months i.e., patient is in a state or has a diagnosis where the cluster physician would not be surprised if patient dies within the next months (this criterion is relatively vague and subjective but because there is no validated prognostic score, it is justified) * Inability to provide informed consent (e.g., because of cognitive impairment), except if a proxy can provide consent, be actively involved in the study, and patient shows no sign of disagreement

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benzodiazepines deprescribing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parasomnias

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire CHU UCL Namur

    Yvoir, 5530, Belgium

  • Department of General Internal Medicine, University Hospital Bern (Inselspital)

    Bern, 3010, Switzerland

  • Institute of Psychiatry and Neurology

    Warsaw, 02-957, Poland

  • National and Kapodistrian University of Athens

    Athens, 10679, Greece

  • Oslo University Hospital

    Nydalen, 4950, Norway

  • Universitat Autònoma de Barcelona

    Barcelona, 08041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.